LI Xin-yan, XU Ying-ying, LIN Jia-li. New Option for Neoadjuvant Therapy for HER2-Positive Breast Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(3): 136-138. DOI: 10.12019/j.issn.1671-5144.2019.03.004
|
Citation:
|
LI Xin-yan, XU Ying-ying, LIN Jia-li. New Option for Neoadjuvant Therapy for HER2-Positive Breast Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(3): 136-138. DOI: 10.12019/j.issn.1671-5144.2019.03.004
|
LI Xin-yan, XU Ying-ying, LIN Jia-li. New Option for Neoadjuvant Therapy for HER2-Positive Breast Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(3): 136-138. DOI: 10.12019/j.issn.1671-5144.2019.03.004
|
Citation:
|
LI Xin-yan, XU Ying-ying, LIN Jia-li. New Option for Neoadjuvant Therapy for HER2-Positive Breast Cancer[J]. Journal of Evidence-Based Medicine, 2019, 19(3): 136-138. DOI: 10.12019/j.issn.1671-5144.2019.03.004
|
DownLoad: